双生长抑素受体/18F-FDG PET/CT显像在分化良好、2级和3级胃肠胰神经内分泌肿瘤患者中的应用
这项单臂前瞻性研究纳入40例组织学证实的分化良好胃肠胰神经内分泌肿瘤患者,在21天内完成68Ga-DOTATATE PET和18F-FDG PET,评估NETPET评分分布及其对临床管理的影响。结果显示NETPET评分分布异质,超过1/5患者为高NETPET评分,42.5%患者在接受18F-FDG PET后管理方式发生改变。
要点
- 40例分化良好2级或3级胃肠胰神经内分泌肿瘤患者中,NETPET评分分布异质。
- 超过1/5患者为高NETPET评分(P3-P5)。
- 18F-FDG PET后42.5%患者的管理类型发生改变。
核心结论
- 分化良好2级和3级胃肠胰神经内分泌肿瘤患者的NETPET评分分布异质,超过1/5患者具有高NETPET评分,且18F-FDG PET后管理方式频繁改变。
- 目标病灶的18F-FDG/68Ga-DOTATATE SUVmax比值和FTV/MTV比值等定量参数可区分高与低NETPET评分患者。
研究设计与样本
- 单臂、机构伦理审查委员会批准的前瞻性研究,纳入40例组织学证实的分化良好胃肠胰神经内分泌肿瘤患者。
- 68Ga-DOTATATE PET与18F-FDG PET在彼此间隔21天内完成。
- NETPET评分由2名评审者定性评估,每例患者最多选择10个标记病灶。
主要发现
- 22例男性、18例女性,平均年龄60.8岁;2级肿瘤24例,3级肿瘤16例;平均Ki-67指数16.1%。
- NETPET评分P0、P1、P2A、P2B、P3B、P4B、P5分别见于2例(5%)、5例(12.5%)、5例(12.5%)、20例(50%)、2例(5%)、4例(10%)、2例(5%)患者。
- 68Ga-DOTATATE目标病灶SUVmax与18F-FDG PET目标病灶SUVmax之间无关联(P=0.505)。
- 低(P1-P2)原发NETPET评分患者18F-FDG/68Ga-DOTATATE SUVmax比值显著低于高(P3-P5)评分患者(均值±标准差,0.20±0.13 vs 1.68±1.44,P<0.001)。
- 低原发NETPET评分患者18F-FDG PET的MTV显著低于高评分患者(均值±标准差,464±601 cm3 vs 66±114 cm3,P=0.005)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our purpose was to prospectively assess the distribution of NETPET scores in well-differentiated (WD) grade 2 and 3 gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) and to determine the impact of the NETPET score on clinical management. Methods: This single-arm, institutional ethics review board-approved prospective study included 40 patients with histologically proven WD GEP NETs. 68Ga-DOTATATE PET and 18F-FDG PET were performed within 21 d of each other. NETPET scores were evaluated qualitatively by 2 reviewers, with up to 10 marker lesions selected for each patient. The quantitative parameters that were evaluated included marker lesion SUVmax for each tracer; 18F-FDG/68Ga-DOTATATE SUVmax ratios; functional tumor volume (FTV) and metabolic tumor volume (MTV) on 68Ga-DOTATATE and 18F-FDG PET, respectively; and FTV/MTV ratios. The treatment plan before and after 18F-FDG PET was recorded. Results: There were 22 men and 18 women (mean age, 60.8 y) with grade 2 (n = 24) or grade 3 (n = 16) tumors and a mean Ki-67 index of 16.1%. NETPET scores of P0, P1, P2A, P2B, P3B, P4B, and P5 were documented in 2 (5%), 5 (12.5%), 5 (12.5%) 20 (50%), 2 (5%), 4 (10%), and 2 (5%) patients, respectively. No association was found between the SUVmax of target lesions on 68Ga-DOTATATE and the SUVmax of target lesions on 18F-FDG PET (P = 0.505). 18F-FDG/68Ga-DOTATATE SUVmax ratios were significantly lower for patients with low (P1-P2) primary NETPET scores than for those with high (P3-P5) primary NETPET scores (mean ± SD, 0.20 ± 0.13 and 1.68 ± 1.44, respectively; P < 0.001). MTV on 18F-FDG PET was significantly lower for low primary NETPET scores than for high ones (mean ± SD, 464 ± 601 cm3 and 66 ± 114 cm3, respectively; P = 0.005). A change in the type of management was observed in 42.5% of patients after 18F-FDG PET, with the most common being a change from systemic therapy to peptide receptor radionuclide therapy and from debulking surgery to systemic therapy. Conclusion: There was a heterogeneous distribution of NETPET scores in patients with WD grade 2 and 3 GEP NETs, with more than 1 in 5 patients having a high NETPET score and a frequent change in management after 18F-FDG PET. Quantitative parameters including 18F-FDG/68Ga-DOTATATE SUVmax ratios in target lesions and FTV/MTV ratios can discriminate between patients with high and low NETPET scores.
引用
- Metser U, Nunez JE, Chan D, et al. Dual Somatostatin Receptor/18F-FDG PET/CT Imaging in Patients with Well-Differentiated, Grade 2 and 3 Gastroenteropancreatic Neuroendocrine Tumors. J Nucl Med. 2024. PMID: 39266292. doi:10.2967/jnumed.124.267982
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。